The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Feb 2003
Randomized Controlled Trial Multicenter Study Clinical TrialOmalizumab improves asthma-related quality of life in patients with severe allergic asthma.
We have previously shown that omalizumab, a recombinant humanized monoclonal anti-IgE antibody, reduces asthma exacerbations and decreases inhaled corticosteroid (ICS) requirement in patients with severe allergic asthma who were symptomatic despite moderate-to-high doses of ICSs. ⋯ In patients requiring moderate-to-high doses of ICSs for severe allergic asthma, the measurably improved disease control afforded by add-on omalizumab therapy is paralleled by clinically meaningful improvements in asthma-related QOL.